#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Asthma Dermatitis atopic Dementia Alzheimer's type Type 2 diabetes mellitus Breast cancer metastatic Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Glomerulonephritis acute Pulmonary alveolar haemorrhage Malignant oligodendroglioma Myxofibrosarcoma Follicle centre lymphoma follicular grade I II – III refractory Pancreatic neuroendocrine tumour Focal segmental glomerulosclerosis Hairy cell leukaemia Chronic hepatitis B Oesophageal achalasia Cryoglobulinaemia X-linked lymphoproliferative syndrome Autoimmune haemolytic anaemia Glomerulonephritis membranous Metastatic gastric cancer More trials…

    Learn about Rare Diseases

    Synovial sarcoma – Diagnostics Haemophagocytic lymphohistiocytosis Combined immunodeficiency – Trials in Disease Glomerulonephritis membranoproliferative – Trials in Disease Turner’s syndrome – Basic Information Congenital generalised lipodystrophy – Trials in Disease Alexander disease Carcinoid syndrome – Trials in Disease Systemic sclerosis pulmonary – Life with Disease Waldenstrom’s macroglobulinaemia – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Acoramidis Caraway Oil Clindamycin Denosumab Elvn-002-1 Milademetan IMEROPRUBART Reparixin Glutenin Dulaglutide Colistin Sulfate Minzasolmin Niraparib Tildacerfont Star-0215 Sufentanil Calcium Levofolinate CYCLIZINE HYDROCHLORIDE Imipenem ARGININE GLUTAMATE More therapies…

    Learn about Your Condition

    Muscle hypertrophy Arteriospasm coronary Thrombotic microangiopathy Lung transplant Meniscus operation Acquired ATTR amyloidosis Cystic fibrosis Cervix carcinoma stage III Myotonic dystrophy Synovitis Astrocytoma malignant CDKL5 deficiency disorder Pericarditis Follicular lymphoma stage III Renal cancer More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Brain Research Center Den Bosch B.V.

Brain Research Center Den Bosch B.V.

Statenlaan 37, s-Hertogenbosch, 5223 LA, Netherlands

Want to learn more about this study or check if you can participate? Contact us.

  • N1T-MC-MALO: A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Who Are at Increased Risk of Developing Major Adverse Liver Outcomes (SYNERGY-Outcomes); N1T-MC-TZ01 Tirzepatide in participants with high-risk MASLD; N1T-MC-RT01 Retatrutide in participants with high-risk MASLD

    Recruiting

    3 1
    Investigated Diseases:
    • Metabolic dysfunction-associated liver disease
    Investigated Drugs:
    • Ly3437943 Sodium
    • Tirzepatide
    Austria Belgium Bulgaria Czechia France Germany +9

  • A study comparing prasinezumab with placebo for people with early-stage Parkinson’s disease

    Recruiting

    3 1
    Investigated Diseases:
    • Parkinson’s disease
    Investigated Drugs:
    • Prasinezumab
    Austria Denmark France Germany Italy The Netherlands +3

  • Study of xanomeline tartrate and trospium chloride combination for cognitive impairment in people with mild to moderate Alzheimer’s disease

    Recruiting

    3 1
    Investigated Diseases:
    • Dementia Alzheimer’s type
    Investigated Drugs:
    • Trospium Chloride
    • Xanomeline Tartrate
    Croatia Czechia Germany Greece Italy The Netherlands +3

  • Study of KarXT (trospium chloride and xanomeline tartrate) and KarX-EC (xanomeline tartrate) for cognitive impairment in mild to moderate Alzheimer’s disease

    Recruiting

    3 1
    Investigated Diseases:
    • Dementia Alzheimer’s type
    Investigated Drugs:
    • Trospium Chloride
    • Xanomeline Tartrate
    Finland France Germany Greece Italy The Netherlands +4

  • Safety and Tolerability Study of NBI-1065845 as Additional Treatment for Adults with Major Depressive Disorder

    Recruiting

    3 1 1
    Investigated Drugs:
    • 9-(4-CYCLOHEXYLOXYPHENYL)-7-METHYL-3,4-DIHYDROPYRAZINO[2,1-C][1,2,4]THIADIAZINE 2,2-DIOXIDE
    Belgium Bulgaria Croatia Czechia Estonia Finland +10

  • Study of MK-2214 to slow disease progression in people with early Alzheimer’s disease

    Recruiting

    2 1
    Investigated Drugs:
    • Florquinitau (18F)
    Belgium The Netherlands Spain

  • Study of vicadrostat and empagliflozin combination in patients with type 2 diabetes, high blood pressure and cardiovascular disease

    Recruiting

    3 1 1
    Investigated Diseases:
    • Cardiovascular disorder
    • Hypertension
    • Type 2 diabetes mellitus
    Investigated Drugs:
    • Bi 690517
    • Empagliflozin
    Austria Belgium Bulgaria Croatia Czechia Denmark +17

  • Study of VHB937 to evaluate its effects on cognition and function in people with early Alzheimer’s Disease over 72 weeks

    Recruiting

    2 1
    Investigated Diseases:
    • Dementia Alzheimer’s type
    Investigated Drugs:
    • VHB937
    Czechia France Germany Italy The Netherlands Poland +2

  • Study on Baxdrostat and Dapagliflozin for Preventing Heart Failure in Patients at High Risk

    Recruiting

    3 1 1
    Investigated Drugs:
    • Baxdrostat
    • Dapagliflozin
    Bulgaria Czechia Denmark France Germany Greece +8

  • A study to test if BHV-8000 is effective and safe for adults with early Parkinson’s disease

    Not yet recruiting

    4 1 1
    Investigated Diseases:
    • Parkinson’s disease
    Investigated Drugs:
    • Ioflupane (123I)
    Austria Belgium Czechia France Germany Italy +4
1 2 3
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!